Omada Health, Inc.

As of June 30, 2026, Omada Health, Inc. carries a market capitalization of 1.16B, placing it among publicly traded companies globally. Its enterprise value stands at 969.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Omada Health, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Omada Health, Inc. has 60.61M shares outstanding.

As of June 30, 2026, Omada Health, Inc. trades at a trailing price-to-earnings ratio of 298.49. The price-to-sales ratio is 4.15, and the price-to-book ratio stands at 5.26.

As of June 30, 2026, Omada Health, Inc. trades at an EV/EBITDA multiple of 203.96 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Omada Health, Inc. trades at an EV/FCF ratio of 47.90, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 969.57M versus a market cap of 1.16B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Omada Health, Inc. maintains a current ratio of 3.91, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Omada Health, Inc. posted a return on equity (ROE) of 1.84, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.19, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 1.36, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.89, useful for judging operating efficiency across full business cycles. The company generates approximately 301,509.09 in revenue per employee across its workforce of 899.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 25.97 indicates how many times Omada Health, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 18.62, while the 200-day moving average is 15.33.

Over the twelve months ended June 30, 2026, Omada Health, Inc. generated 271.13M in revenue and converted that into 3.77M in net income, yielding earnings per share of 0.06. EBITDA reached 4.75M, while operating income came in at -406,139.20.

These figures are as of June 30, 2026. Total book value stands at 221.22M, with working capital of 192.07M providing operational flexibility.

Omada Health, Inc. produced 20.73M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -840,288.00 in capital expenditures, free cash flow totaled 19.89M - equivalent to 0.34 per share.

Over the twelve months ended June 30, 2026, Omada Health, Inc. posted a gross margin of 68.19, reflecting its pricing power and cost economics. The operating margin of -0.15 and net profit margin of 1.39 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.70, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.40, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Omada Health, Inc. shareholders.

As of June 30, 2026, Omada Health, Inc. has an Altman Z-Score of 10.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.